Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients

Sultan Abdul-Jawad, Luca Baù, Thanussuyah Alaguthurai, Irene Del Molino Del Barrio, Adam G Laing, Thomas S Hayday, Leticia Monin, Miguel Muñoz-Ruiz, Louisa McDonald, Isaac Francos Quijorna, Duncan McKenzie, Richard Davis, Anna Lorenc, Julie Nuo En Chan, Sarah Ryan, Eva Bugallo-Blanco, Rozalyn Yorke, Shraddha Kamdar, Matthew Fish, Iva ZlatarevaPierre Vantourout, Aislinn Jennings, Sarah Gee, Katie Doores, Katharine Bailey, Sophie Hazell, Julien De Naurois, Charlotte Moss, Beth Russell, Aadil A Khan, Mark Rowley, Reuben Benjamin, Deborah Enting, Doraid Alrifai, Yin Wu, You Zhou, Paul Barber, Tony Ng, James Spicer, Mieke Van Hemelrijck, Mayur Kumar, Jennifer Vidler, Yadanar Lwin, Paul Fields, Sophia N Karagiannis, Anthony C C Coolen, Anne Rigg, Sophie Papa, Adrian C Hayday, Piers E M Patten, Sheeba Irshad

Research output: Contribution to journalArticlepeer-review

79 Citations (Scopus)


Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19 + non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

Original languageEnglish
Pages (from-to)257-275.e6
Issue number2
Early online date5 Jan 2021
Publication statusPublished - 8 Feb 2021


Dive into the research topics of 'Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients'. Together they form a unique fingerprint.

Cite this